Later Line Therapeutic Decisions in Metastatic HCC: Case 2
Later Line Therapeutic Decisions in Metastatic HCC
January 2017
- A 74-year old female with a history of HCV-infection
- Prior treatment with interferon, achieving sustained virologic response
- Had recurrence of HCV
- CT scan showed a 6.5-cm single liver mass with arterial enhancement, venous phase washout, and main portal vein invasion
- ECOG=1
- Child-Pugh A
- Therapy was initiated with sorafenib at 400 BID
- Patient experienced grade 3 hand-foot skin reaction; dose reduction to 400 QD
- Patient experienced grade 3 diarrhea; dose reduction to 400 QOD
April 2017
- Follow-up scans show radiographic progression with lung metastases
Recent Videos
Related Content
FDA Receives Resubmitted NDA for Camrelizumab/Rivoceranib Combo in Unresectable HCC
September 24th 2024Article
A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma, following a complete response letter in May 2024.
Read More
